Business

Know the Business

Centene is a government-program insurer dressed in capital-markets clothing: 79% of premium comes from Medicaid, the ACA Marketplace and Medicare, and what looks like a $195B revenue giant earns its keep on a few hundred basis points of medical-cost discipline. The thesis hinges on whether 2025 is a one-bad-cycle reset — medical loss ratios snapped from 88.3% to 91.9%, FY2025 booked a $6.7B goodwill write-down and a GAAP loss of $13.53/share — or whether structural changes (OBBBA, EAPTC sunset, Medicaid morbidity) have permanently lowered the earnings power. The market is pricing it like the latter (forward P/E ~14, stock at half its 52-week high), but adjusted EPS still printed $2.08 and operating cash flow was $5.1B.

1. How This Business Actually Works

Centene is a regulated middleman: states and CMS hand it a fixed monthly premium per enrollee (PMPM), and it pockets whatever sliver remains after paying doctors, hospitals and pharmacies. Pricing is set 12–18 months in advance through state rate filings and CMS bids — so the business eats any cost-trend miss until rates catch up.

The right-hand chart is the entire business in one picture. On every premium dollar, ~92 cents goes to medical care (HBR), ~7 cents to SG&A, leaving ~1 cent of operating margin. That razor-thin spread is why a 100 bps move in HBR is the difference between a good year and a write-down year — and 2025 brought a 360 bps move.

Three sources of incremental profit matter:

• Rate-to-trend gap. Medicaid rates are renegotiated state-by-state, often annually. When morbidity rises faster than the actuaries assumed (as it has since redeterminations and OBBBA), profit gets crushed until the next rate cycle. CNC's 2025 Medicaid composite rate update was 5.5% — but trend ran higher.
• Mix. Higher-acuity members (ABD, LTSS, dual-eligibles) carry larger PMPMs but also larger absolute dollars at risk. Marketplace and PDP throw off lower SG&A ratios because they leverage existing infrastructure. The PDP-revenue surge (IRA-driven premium inflation, +17% members) is the single largest 2025 SG&A leverage story.
• Risk-adjustment / risk-corridors. Marketplace risk transfers (paying or receiving from sicker/healthier peers) and Medicare Part D risk corridors are accounting cushions that move earnings by hundreds of millions per quarter — the $2.4B FY2025 Marketplace morbidity hit is the marquee example.

There is no real moat in price; the moat — to the extent it exists — is being the incumbent on 30 state Medicaid contracts, the largest Marketplace footprint (Ambetter in 29 states), and the largest stand-alone PDP (8.1M members). Switching costs for a state are high: re-procurement is multi-year, politically risky, and the operational lift of moving millions of members is enormous.

2. The Playing Field

The peer set splits cleanly into two camps: vertically integrated giants (UNH, ELV, CI) that earn most of their economic profit outside health insurance, and pure-play managed-care plays (CNC, HUM, MOH) where the insurance margin is the business. Centene sits in the second camp and looks the most like Molina with a much bigger Marketplace and PDP book.

Two takeaways from the peer set:

• 2025 was bad for everyone, but worst for Centene. UNH and ELV both saw operating margins compress 200–400 bps from medical-cost trend; HUM is a near-permanent margin laggard tied to Medicare Advantage trend. Centene is the only peer at a GAAP operating loss, and that loss is overwhelmingly the goodwill write-down — strip it out and CNC is roughly breakeven on $195B of revenue, still the worst of the group. The fact that every peer's HBR is 89–92% confirms this is industry cycle, not company-specific failure.
• The market gives no credit. CNC trades at the lowest EV/Revenue in the group (~0.11x) and a mid-teens forward P/E that implies street consensus that adjusted EPS recovers to ~$3 by 2027. UNH still commands 0.7x EV/Revenue and a 20x multiple because Optum (PBM, care delivery, data) is structurally insulated from the underwriting cycle. CNC has no such hedge — the entire P&L sits on the underwriting side.

3. Is This Business Cyclical?

Yes — but the cycle is regulatory and medical-trend driven, not macroeconomic. Centene's beta of 0.59 says recessions don't hurt much; in fact, downturns help by expanding Medicaid and Marketplace eligibility. What hurts is the gap between when medical costs accelerate and when state rate filings or CMS bids catch up. That gap closed in 2017–2019 (post-ACA), reopened in 2021 (COVID), and reopened again hard in 2024–2025.

The HBR chart is the cycle; net margin is the consequence. Three concrete cyclical mechanics worth understanding:

• Medicaid redeterminations stripped 3.6M members starting March 2023. The members who left were disproportionately healthy; the ones who stayed are sicker. State rate filings lagged this acuity shift, which is the single biggest reason Medicaid HBR ran above plan in 2024–2025.
• The Marketplace cycle is sharper. ACA enhanced subsidies (EAPTC) expired at end-2025. Management's own range for 2026 Marketplace contraction is "high teens to mid-thirties" — meaning 1–2M of CNC's 5.5M Ambetter members may not re-enroll. The members who do re-enroll will be sicker (adverse selection), which is why CNC took mid-30% rate hikes for 2026.
• PDP got rewired by the IRA in 2025. The $2,000 out-of-pocket cap shifted catastrophic drug cost from members onto plans — premiums jumped, membership grew 17%, and CMS narrowed risk corridors as a temporary cushion. CMS removed the corridor cushion for 2026, so 2025 PDP outperformance is a known headwind into 2026.

4. The Metrics That Actually Matter

Five numbers explain almost everything. Reported revenue, EBITDA and even GAAP EPS are noise on top of these.

Pay attention to the FY2024–FY2025 swap. FY2024 looked great on net income ($3.3B) but FCF was negative $490M because risk-adjustment receivables and CMS pass-throughs ballooned. FY2025 looked catastrophic on net income (–$6.7B) but FCF rebounded to $4.3B because the goodwill write-down was non-cash and the receivables unwound. In an insurance business, operating cash flow leads earnings by 12–18 months — it's the better real-time signal.

5. What I'd Tell a Young Analyst

This is a one-variable stock right now: does HBR mean-revert from 91.9% back toward the 87–88% historical band by 2027? If yes, adjusted EPS rebuilds to $5–7 and the stock re-rates from a 14x crisis multiple to a normalized 12–14x on $5+ — a double. If no — if OBBBA, work requirements and Marketplace adverse selection have permanently raised the structural HBR — then $2 of EPS at 14x is the right price and there's no margin of safety.

Three things to watch that would actually move the thesis:

• Q1 and Q2 2026 Medicaid HBR prints. Management is guiding "Medicaid profitability consistent with 2025" for 2026, with the back-half 2025 HBR improving to ~93.2%. If Q1 26 prints below 93%, the rate-catch-up is working. If it prints above 93.5%, the bear case is winning.
• Marketplace 2026 enrollment vs the high-teens-to-mid-thirties contraction range. The mid-30% rate hikes are aggressive — if competitors didn't price as hard, CNC loses share but holds margin (good); if everyone hiked similarly, the market shrinks and CNC's pricing holds (also good). The bad scenario is competitors stayed disciplined while CNC overshot, losing both share and members.
• 2027 Medicare Advantage breakeven milestone. This is management's anchor target. The 2026 Star Ratings (60% in 3.5+) make it credible. A miss here would force a fundamental rethink of whether the Wellcare franchise is structurally sub-scale.

What the market may be underestimating: the D-SNP mandate kicking in 2027–2030 forces dual-eligibles into integrated plans owned by their existing Medicaid carrier. Centene's overlapping Medicaid + MA footprint is the best in the industry for this — it's the closest thing CNC has to a structural moat, and it's not in the multiple.

What the market may be overestimating: the durability of the impairment as "non-cash." It is non-cash, but it is also a board-level admission that $6.7B of acquired goodwill (largely WellCare, 2020) is no longer worth its carrying value — i.e., the M&A roll-up that built modern Centene was overpaid. That should color how generously you credit future M&A.

Watch the cash flow statement before the income statement. Watch state-by-state rate filings before the consensus model. And remember: this business earns its keep on a sub-1% spread between premium and medical cost — when that spread closes, scale doesn't help.